Citi analyst Yigal Nochomovitz lowered the firm’s price target on Cellectis (CLLS) to $10 from $12 and keeps a Buy rating on the shares. The analyst updated the company’s model post the Q3 report. The firm cites dilution from the recent AstraZeneca (AZN) equity investment, partially offset by potential milestone revenues from the collaboration and higher cash, for the target drop.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLLS:
- Cellectis’ Shareholders Meeting to be Held on December 22, 2023
- Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
- Cellectis reports Q3 EPS (31c), consensus (42c)
- Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
- CLLS Upcoming Earnings Report: What to Expect?